The Best-Selling Drug in History Just Lost a Head-to-Head Trial
A Chinese-invented drug just beat Merck's Keytruda on overall survival — a first. What it means for pharma's biggest franchise, the PD-1/VEGF gold rush, and Summit Therapeutics' $14 billion valuation.
(SEOUL) — On Sunday morning at the World Conference on Lung Cancer, a Chinese-developed drug did something no medicine has ever done: it beat Merck's Keytruda on overall survival in a head-to-head randomized trial.
Not progression-free survival, the softer endpoint that measures how long scans stay clean. Overall survival — whether patients are alive. In the Phase 3 HARMONi-2 trial, patients with PD-L1-positive advanced non-small cell lung cancer who received ivonescimab lived a median of 30.8 months, versus 22.6 months on Keytruda. That is an eight-month gap against the most successful drug in pharmaceutical history, a 27% reduction in the risk of death (hazard ratio 0.73, p=0.009).
To understand why this matters for markets, you need to understand what Keytruda is to Merck. Pembrolizumab did $29.5 billion in sales in 2024 — the best-selling drug on Earth, approaching half of Merck's entire revenue. It is the standard first-line treatment for the largest cancer indication in oncology, non-small cell lung cancer. And its key US patent protection begins expiring in 2028. Merck's entire equity story for the past three years has been a single question: what fills the hole?
The drug that just beat it was invented not in Rahway or Basel but by Akeso, a biotech out of Zhongshan, China. Ivonescimab is a bispecific antibody — one molecule that blocks PD-1 (Keytruda's target) and VEGF (Avastin's target) simultaneously. In late 2022, a then-obscure company called Summit Therapeutics licensed the Western rights for $500 million upfront — a deal engineered by Bob Duggan, the billionaire who built Pharmacyclics and sold it to AbbVie for $21 billion. Wall Street mostly shrugged.
It stopped shrugging in September 2024, when HARMONi-2 first read out: ivonescimab roughly doubled progression-free survival versus Keytruda (11.1 vs. 5.8 months). But skeptics had a ready answer — PFS is not survival, and VEGF-added regimens have a long history of shrinking tumors without extending lives. Show us overall survival, they said, expecting the effect to fade.
Sunday's late-breaker was the answer. The survival benefit was strongest exactly where the commercial stakes are highest: in PD-L1-high patients — the population where Keytruda monotherapy is the undisputed global standard — the hazard ratio was 0.58, a 42% reduction in the risk of death. Squamous histology, historically the hardest to treat: 0.65. Safety was broadly comparable, with no new signals on extended follow-up.
Summit's stock has responded: up roughly 35% since the survival win was first announced on September 2, closing near $18.40 today for a market capitalization around $13–14 billion — for a company with no revenue. Jefferies upgraded it to Buy last week.
So the obvious questions: Is the most important franchise in pharma now in managed decline? Is Summit — a pre-revenue biotech priced like a mid-cap pharma — still cheap, or already priced for perfection? There are three catches in this data that most of the coverage is skipping, and they determine both answers.
Get the next briefing free in your inbox: Join AlphaBriefing
The rest of this briefing is for paid members: the three catches in the HARMONi-2 data (including the subgroup where the benefit statistically disappears), the full PD-1/VEGF deal map — what Pfizer, Bristol Myers, and Merck each paid for their tickets — the catalyst calendar for Summit through 2027, and the scenario framework for both SMMT and MRK.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.